Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma

Acta Oncologica

Volumn 48, Issue 4, 2009, Pages 619-621

  Azad, Arun ^a   Herbertson, Rebecca A ^b   Pook, David ^b   White, Shane ^a   Mitchell, Paul L R ^a   Tebbutt, Niall C ^a,b  

^a AUSTIN HEALTH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MOTESANIB; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE;

ADULT; ANAMNESIS; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PLEURA DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYMOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; METASTASIS; MINIMAL RESIDUAL DISEASE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PLEURA TUMOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; HUMANS; INDOLES; MALE; NEOPLASM, RESIDUAL; NIACINAMIDE; PLEURAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; THYMOMA; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 65549163439     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802495362     Document Type: Letter

References (6)

1. Cimpean AM, Raica M, Encica S, Cornea R, Bocan V. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008;/190:/238-45.
2. Bedano PM, Perkins S, Burns M, Kessler K, Nelson R, Schneider BP, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008;/26(Suppl) (Abstract 19087).
3. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 2008;/26(Suppl) (Abstract 3599).
4. Fiedler WM, Giaccone G, Lasch P, Van der Horst I, Brega NM, Raber S, et al. Phase I trial of SU014813 in patients (pts) with advanced solid malignancies. J Clin Oncol (Meeting Abstracts). 2007;25(18 Suppl):3521.
5. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;/25:/2369-76.
6. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. New Engl J Med 2008;/359:/ 31-42.